Vonoprazan based therapy versus proton pump inhibitor based therapy for eradication of Helicobacter pylori: A randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202507832291336

Enrollment

100

Registered

2025-07-28

Start date

2024-07-22

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System H.Pylori infection

Interventions

Vonoprazan based therapy

PPI based therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient who has H.pylori infection detected by stool antigen test (SAT)

Exclusion criteria

Exclusion criteria: Prior H.pylori eradication therapy. Recent intake of antibiotics, PPI, H2 receptor blockers, nonsteroidal or anti-inflammatory drugs, within the last month Allergy of any of the antibiotics used in the study Gastrointestinal malignancy. Active upper gastrointestinal bleeding. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
eradication of H pylori infection by SAT	—

Secondary

Measure	Time frame
side effect of Vonoprazan containing regimen	—

Countries

Egypt

Contacts

Public ContactAhmed Qasem

Professor of Hepatology and Gastroenterology

Aqasem97@yahoo.com01009239963

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026